In the excitement of global drug launches, a critical issue often overlooked is the lack of local clinical evidence in many Asia-Pacific countries. This gap forces healthcare providers to rely on Western data, which may not be applicable to the region’s vast, genetically diverse populations. Consequently, this gap leads to hesitancy among doctors, delays in regulatory approvals, and ultimately, denied access to effective treatments for patients.
Authored by industry experts Ankit Kulshrestha, Dr. Mahendra Rai, and Dr. Romik Ghosh, the white paper proposes practical alternatives to traditional randomized controlled trials—such as KAP surveys, literature reviews, pooled analyses, and discrete choice experiments—to deliver credible local evidence more efficiently, helping to bridge the gap and ensure timely access to treatments for APAC patients.
The paper emphasizes the strategic implications of generating local evidence, including improved launch readiness, better payer engagement, agility in strategy shifts, efficiency, and stronger relationships with local clinicians.
Read the full article for insights and strategies that can turn APAC’s evidence gap into a leadership story.
Complete the form below to download the full paper.
Author Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…